A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors

Manuel A. Castello, Anna Clerico, Alessandro Jenkner, Carlo Dominici

Research output: Contribution to journalArticle

Abstract

Carboplatin was administered at 1,000 mg/m2/course in combination with etoposide at 300 mg/m2/course to 23 patients aged 5 months to 16 years. Five patients were affected by neuroblastoma, four by CNS tumors, three by Ewing's sarcoma, two by rhabdomyosarcoma, two by malignant teratoma, two by Wilms' tumor, two by head and neck carcinoma, one by hepatoblastoma, one by synovial sarcoma, and one by Langerhans-cell histiocytosis. Eleven patients were pretreated, seven of them with high-dose cisplatin. The overall response rate was 7/11 (64% for pretreated and 10/12 (83% for previously untreated patients. Myelosuppression was the main side effect, with anemia and thrombocytopenia more pronounced than leukopenia. Gastrointestinal toxicity and ototoxicity were very mild; nephrotoxicity and neurotoxicity other than hearing loss were not observed. In children with malignant tumors, the therapeutic activity of carboplatin at high doses, even in combination chemotherapy, deserves further studies.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalPediatric Hematology and Oncology
Volume7
Issue number2
DOIs
Publication statusPublished - 1990

Keywords

  • Carboplatin
  • Childhood tumors
  • Etoposide
  • Myelosuppression
  • Ototoxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Fingerprint Dive into the research topics of 'A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors'. Together they form a unique fingerprint.

  • Cite this